Atara Biotherapeutics (USA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, announced that it has entered into a strategic collaboration with Moffitt Cancer Center to develop multi‑targeted chimeric antigen receptor T-cell (CAR T) immunotherapies for patients with AML and B‑cell malignancies.
As part of the collaboration, Atara will gain access to novel CAR T targeting and co‑stimulation domains designed to improve T cell proliferation and enhance persistence. This agreement, along with Atara’s prior CAR T collaboration with Memorial Sloan Kettering Cancer Center (MSK), furthers the company’s strategy to develop next generation engineered CAR T immunotherapies across multiple therapeutic areas and leverage the Company’s off-the-shelf, allogeneic T-cell immunotherapy platform.
Under the agreement, Atara will collaborate with Dr. Davila to develop multi-targeted CAR T immunotherapies designed to address cancers with diverse cell types that often become resistant to treatment such as AML and B-cell malignancies. In addition, the collaboration includes the use of novel CAR T intracellular co-stimulatory domains based on CD28 and 4-1BB that may improve CAR T proliferation when responding to an appropriate antigen and enhance CAR T persistence by reducing T cell exhaustion.
Founded in 2012 and headquartered in South San Francisco (USA), Atara Biotherapeutics was named after Atara Ciechanover who suffered from cancer before passing away. As an off-the-shelf T-cell immunotherapy company, Atara Therapeutics develops treatments for patients with cancer, autoimmune, and viral diseases.
Based in Tampa, Florida (USA), Moffitt Cancer Center has made a lasting commitment to the prevention and cure of cancer, working tirelessly in the areas of patient care, research and education to advance one step further in fighting this disease.